Effect of CTLA-4-Ig on human B lymphocyte function and specificity for citrullinated protein antigens in rheumatoid arthritis (RA)
- Conditions
- Rheumatoid Arthritis
- Registration Number
- DRKS00012864
- Lead Sponsor
- niversitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
rheumatoide arthritis
informed consent
treatment with abatacept
treatment start after 01.01.2015
Exclusion Criteria
prior therapy with ritxuimab, JAk-Inhibitors, cyclophosphamide
malignant disease
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in B cell compartment and titers of autoantibodies: <br>- blood specimens drawn 3, 6 and 12 month after start of therapy will be analyzed for<br>a, B cell subpopulations (naive, marginal zone, memory)<br>b, titers of ccP-antibodies
- Secondary Outcome Measures
Name Time Method Changes in ACPA reactivity 3,6 and 12 months after start of therapy